Company / Shareholders' Equity
Moleculin Biotech, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$11.2M
FY2025
5-year range
$11.2M / $79.0M
FY2021-FY2025
Trend
-57.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $79M in FY2022 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of -6.4%.
Declined from $52M to $11M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -47.8%
- 5-Year CAGR
- -6.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Moleculin Biotech, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -6.4%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 57.0% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.2M | -57.0% |
| FY2024 | $26.1M | -50.0% |
| FY2023 | $52.2M | -33.9% |
| FY2022 | $79.0M | +344.8% |
| FY2021 | $17.8M | +14.1% |
| FY2020 | $15.6M | +9.1% |
| FY2019 | $14.3M | -16.6% |
| FY2018 | $17.1M | +14.4% |
| FY2017 | $15.0M | +2108.9% |
| FY2016 | -$744.7K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026